ProBio: HRQoL for mCRPC patients treated with androgen receptor pathway inhibitors

ProBio is a biomarker driven platform trial in patients with metastatic castration-resistant prostate cancer (mCRPC), evaluating different treatment classes across multiple biomarker signatures. Health related quality of life (HRQoL) is an important secondary endpoint of this study, and the results of this analysis were reported as a poster during the 2024 annual ESMO meeting. In this video, Dr Renée Bultijnck takes us through the key take-aways from this analysis.

The ProBio study enrolled a total of 151 patients and randomly assigned them to receive an androgen receptor pathway inhibitor (ARPI), a taxane or physician’s choice standard of care (SoC). The evolution of the HRQoL was measured every three months for 3 years using the EORTCQLQ-C30 questionnaire. During the first 6 months the global QoL score improved in the ARPI group and subsequently declined over time. In contrast, immediate decreases in global health were observed in the taxane and SoC groups. At six months, this translated into a mean difference in global QoL score between ARPI and a taxane or ARPI and SoC of 11.8 and 16.3 points, respectively. In addition, ARPI demonstrated a lower cumulative risk of deterioration in global QoL scores over time compared to both SoC and a taxane.

In conclusion, ARPI-treated mCRPC patients experience an initial improvement in HRQoL and have a better overall HRQoL than those receiving a taxane or physician’s choice SoC.